Experts are excitedly investigating retatrutide, a promising drug developed by Eli Lilly, as a possible step in body management. Distinct from many previous approaches, retatrutide is a double -action agonist targeting simultaneously GLP-1 and GIP, hormones that impact hunger and blood glucose bala